DRAX EXAMETAZIME
Peakkit for the preparation of technetium tc 99m exametazime for leukocyte labeling
NDAINTRAVENOUSPOWDER
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DRAX EXAMETAZIME (kit for the preparation of technetium tc 99m exametazime for leukocyte labeling) by Jubilant Therapeutics is radiopharmaceutical activity [moa]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRAX EXAMETAZIME is a radiopharmaceutical kit for preparing Technetium Tc-99m exametazime, a diagnostic agent used to label white blood cells (leukocytes) for imaging infections and inflammation. The radiolabeled leukocytes are administered intravenously to localize areas of infection, abscess, or inflammatory disease through gamma scintigraphy. This is a niche diagnostic tool in nuclear medicine, enabling clinicians to visualize leukocyte distribution in vivo.
Peak
Peak-stage diagnostic radiopharmaceutical with modest competitive pressure (30% intensity); modest-sized commercial teams given niche nuclear medicine positioning.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DRAX EXAMETAZIME offers career stability in a specialized, niche diagnostic market with deep expertise in nuclear medicine and radiopharmaceutical operations. Roles emphasize technical knowledge, hospital relationships, and regulatory compliance rather than high-volume commercial expansion, suited for professionals seeking specialized expertise and lower-velocity commercial environments.
Medical Science Liaison (Nuclear Medicine)
Worked on DRAX EXAMETAZIME at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.